Michael B Bass

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer
    Michael B Bass
    Department of Computational Biology, Amgen Inc, Thousand Oaks, California 91320 1799, USA
    J Clin Endocrinol Metab 95:5018-27. 2010
  2. ncbi Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
    Michael J Boedigheimer
    CDER, US FDA, Silver Spring, MD 20993, USA
    BMC Genomics 9:285. 2008
  3. ncbi Anti-Epo receptor antibodies do not predict Epo receptor expression
    Steve Elliott
    Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Blood 107:1892-5. 2006
  4. ncbi Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice
    Todd Juan
    Department of Metabolic Disorders, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Lipid Res 50:534-45. 2009
  5. ncbi New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification
    Philip Babij
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California 91320, USA
    J Bone Miner Res 24:1552-64. 2009
  6. ncbi Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers
    Sushil K Thukral
    Amgen Inc, Thousand Oaks, California 91320, USA
    Toxicol Pathol 33:343-55. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer
    Michael B Bass
    Department of Computational Biology, Amgen Inc, Thousand Oaks, California 91320 1799, USA
    J Clin Endocrinol Metab 95:5018-27. 2010
    ..Antiangiogenic therapies have shown potential in the treatment of advanced thyroid cancer, but it is uncertain which patients are most likely to benefit from therapy...
  2. ncbi Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
    Michael J Boedigheimer
    CDER, US FDA, Silver Spring, MD 20993, USA
    BMC Genomics 9:285. 2008
    ....
  3. ncbi Anti-Epo receptor antibodies do not predict Epo receptor expression
    Steve Elliott
    Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Blood 107:1892-5. 2006
    ..We concluded that these antibodies have limited utility for detecting EpoR. Thus, reports of EpoR expression in tumor cells using these antibodies should be viewed with caution...
  4. ncbi Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice
    Todd Juan
    Department of Metabolic Disorders, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Lipid Res 50:534-45. 2009
    ..These results illustrate the use of a hybrid background for simultaneous screening and mapping of mutagenized pedigrees of mice and identification of three novel alleles of HDL-cholesterol phenotypes...
  5. ncbi New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification
    Philip Babij
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California 91320, USA
    J Bone Miner Res 24:1552-64. 2009
    ..This work confirms the utility of the chemical mutagenesis approach for identification of potential disease genes and confirms the role of Enpp1 and Ptpn6 in regulating mineralization and skeletal bone mass...
  6. ncbi Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers
    Sushil K Thukral
    Amgen Inc, Thousand Oaks, California 91320, USA
    Toxicol Pathol 33:343-55. 2005
    ..These include several transporters (Slc21a2, Slc15, Slc34a2), Kim 1, IGFbp-1, osteopontin, alpha-fibrinogen, and Gstalpha...